ECSP23091984A - Compuestos y usos de estos - Google Patents
Compuestos y usos de estosInfo
- Publication number
- ECSP23091984A ECSP23091984A ECSENADI202391984A ECDI202391984A ECSP23091984A EC SP23091984 A ECSP23091984 A EC SP23091984A EC SENADI202391984 A ECSENADI202391984 A EC SENADI202391984A EC DI202391984 A ECDI202391984 A EC DI202391984A EC SP23091984 A ECSP23091984 A EC SP23091984A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- treatment
- present description
- compounds useful
- disorders related
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente descripción presenta compuestos útiles para el tratamiento de trastornos relacionados con el complejo BAF.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163186550P | 2021-05-10 | 2021-05-10 | |
| US202263325716P | 2022-03-31 | 2022-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23091984A true ECSP23091984A (es) | 2024-03-01 |
Family
ID=84028816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202391984A ECSP23091984A (es) | 2021-05-10 | 2023-12-06 | Compuestos y usos de estos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240376121A1 (es) |
| EP (1) | EP4337211A4 (es) |
| JP (2) | JP2024516995A (es) |
| KR (1) | KR20240004983A (es) |
| AU (1) | AU2022272181B9 (es) |
| CA (1) | CA3216773A1 (es) |
| CL (1) | CL2023003255A1 (es) |
| CO (1) | CO2023016958A2 (es) |
| CR (1) | CR20230518A (es) |
| DO (1) | DOP2023000244A (es) |
| EC (1) | ECSP23091984A (es) |
| IL (1) | IL307965A (es) |
| JO (1) | JOP20230287A1 (es) |
| MX (1) | MX2023013083A (es) |
| PE (1) | PE20242362A1 (es) |
| TW (1) | TW202313629A (es) |
| WO (1) | WO2022240825A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4695250A1 (en) | 2023-04-12 | 2026-02-18 | Aurigene Oncology Limited | Tetracyclic compounds as smarca2 and/or smarca4 degraders |
| EP4709726A1 (en) * | 2023-05-10 | 2026-03-18 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019249849C1 (en) * | 2018-04-01 | 2022-09-29 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| SG11202104495YA (en) * | 2018-04-26 | 2021-05-28 | Aurigene Discovery Tech Ltd | Pyridazine derivatives as smarca2/4 degraders |
| CN112996800B (zh) * | 2018-10-16 | 2024-06-25 | 勃林格殷格翰国际有限公司 | 作为smarca2和/或smarca4的降解剂的新型蛋白水解靶向嵌合体（protac）及其衍生物 |
| WO2020160193A2 (en) * | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CN114728936A (zh) * | 2019-10-29 | 2022-07-08 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的双功能化合物 |
| JP7508578B2 (ja) | 2020-04-06 | 2024-07-01 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
| US12552775B2 (en) * | 2020-11-20 | 2026-02-17 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US20240024488A1 (en) * | 2020-11-20 | 2024-01-25 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
-
2022
- 2022-05-10 CR CR20230518A patent/CR20230518A/es unknown
- 2022-05-10 PE PE2023003029A patent/PE20242362A1/es unknown
- 2022-05-10 CA CA3216773A patent/CA3216773A1/en active Pending
- 2022-05-10 KR KR1020237041911A patent/KR20240004983A/ko not_active Withdrawn
- 2022-05-10 US US18/288,504 patent/US20240376121A1/en active Pending
- 2022-05-10 AU AU2022272181A patent/AU2022272181B9/en not_active Expired - Fee Related
- 2022-05-10 TW TW111117541A patent/TW202313629A/zh unknown
- 2022-05-10 JP JP2023567909A patent/JP2024516995A/ja active Pending
- 2022-05-10 WO PCT/US2022/028511 patent/WO2022240825A1/en not_active Ceased
- 2022-05-10 MX MX2023013083A patent/MX2023013083A/es unknown
- 2022-05-10 IL IL307965A patent/IL307965A/en unknown
- 2022-05-10 EP EP22808172.5A patent/EP4337211A4/en active Pending
-
2023
- 2023-11-02 CL CL2023003255A patent/CL2023003255A1/es unknown
- 2023-11-03 DO DO2023000244A patent/DOP2023000244A/es unknown
- 2023-11-09 JO JOJO/P/2023/0287A patent/JOP20230287A1/ar unknown
- 2023-12-05 CO CONC2023/0016958A patent/CO2023016958A2/es unknown
- 2023-12-06 EC ECSENADI202391984A patent/ECSP23091984A/es unknown
-
2025
- 2025-11-14 JP JP2025195223A patent/JP2026032043A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2023000244A (es) | 2024-01-31 |
| WO2022240825A1 (en) | 2022-11-17 |
| JP2024516995A (ja) | 2024-04-18 |
| CR20230518A (es) | 2024-02-13 |
| IL307965A (en) | 2023-12-01 |
| JOP20230287A1 (ar) | 2023-11-09 |
| EP4337211A4 (en) | 2025-06-18 |
| CL2023003255A1 (es) | 2024-04-26 |
| TW202313629A (zh) | 2023-04-01 |
| AU2022272181A1 (en) | 2023-11-02 |
| US20240376121A1 (en) | 2024-11-14 |
| JP2026032043A (ja) | 2026-02-25 |
| AU2022272181B9 (en) | 2025-06-26 |
| EP4337211A1 (en) | 2024-03-20 |
| CO2023016958A2 (es) | 2023-12-20 |
| MX2023013083A (es) | 2024-01-08 |
| PE20242362A1 (es) | 2024-12-16 |
| AU2022272181B2 (en) | 2025-06-05 |
| KR20240004983A (ko) | 2024-01-11 |
| CA3216773A1 (en) | 2022-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022010547A2 (es) | Compuestos y usos de los mismos | |
| CL2024001964A1 (es) | Compuestos para la inhibición de nlrp3 y usos de estos | |
| CL2018002505A1 (es) | Inhibidores del envejecimiento proteico-proteico wdr5 | |
| UY40021A (es) | Inhibidores lisina acetiltransferasa 6a (kat6a) y usos de los mismos | |
| ECSP24026455A (es) | Compuestos de pirrolotriazina como inhibidores de tam | |
| MX2022003166A (es) | Moduladores de il-17a y usos de los mismos. | |
| BR112022014949A2 (pt) | Compostos e usos dos mesmos | |
| BR112022015109A2 (pt) | Compostos e usos dos mesmos | |
| MX382671B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| MX384213B (es) | Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias. | |
| MX2016017133A (es) | Bifenil amidas con grupos eter modificados como inhibidores de hsp90 e inductores de hsp70. | |
| BR112016028255A2 (pt) | agentes imunorreguladores | |
| DOP2023000223A (es) | Composiciones y métodos para inhibir cetohexoquinasa (khk) | |
| CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
| BR112017007975A2 (pt) | composições e métodos para o tratamento de disfunção das glândulas meibomianas | |
| DOP2018000219A (es) | Anticuerpos anti-factor bb del complemento y usos de estos | |
| CO2023016958A2 (es) | Compuestos y usos de estos | |
| MX2022014924A (es) | Moduladores de il-17a. | |
| CO2020005420A2 (es) | Compuestos antibacterianos | |
| AR125457A2 (es) | Compuestos inhibidores dobles de magl y faah y composición farmacéutica | |
| MX2021004566A (es) | Compuestos terapeuticos. | |
| CO2022018636A2 (es) | Moduladores de il-17a | |
| CO2022011258A2 (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas | |
| CL2017000827A1 (es) | Inhibidores de aldosterona sintasa | |
| MX2018013164A (es) | Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa. |